Hacker News Reader

The cost to setup a process and maintain it according to FDA requirements.

The market size is likely just under the cost to establish the manufacturing capacity for the US market.

I guess that maintaining the process isn't that expensive, considering the previous price (which, I'm pretty sure, wasn't kept at a loss).

So, probably, it's setting the process up which is expensive.

And yet the "bad guy" generic manufacturer was able to raise the capital to do this (and presumably make a profit). What's the difference?

Turing only acquired the US marketing rights. Someone else is making the drug. So that doesn't change the FDA licensing, but they get to increase the price in the US.

http://www.prnewswire.com/news-releases/turing-pharmaceutica...

Reply on news.ycombinator.com